Docteur Oswald VAN CUTSEM

Docteur Oswald VAN CUTSEM
Pneumologue
Chef de Service
Contacts
secrétariat planning : 081. 20 96 61
secrétariat consultations : 081. 20 94 61
Diplômes :
•
•
Doctorat UCL 1983
Diplôme de spécialiste en pneumologie UCL 1988
Mandats
•
•
•
•
•
Membre de l’European Lung Cancer Working Party
Membre de la Société Belge de Pneumologie
Membre de la Société de Pathologie Thoracique du Nord (France)
Membre de la Société de Pneumologie de langue française
Membre de l’European Respiratory Society
Publications
VAN CUTSEM O., REMY J., WALLAERT B., TONNEL A.B.
Fièvre, douleur et cavité.
Rev. Mal. Resp. 1988, 5, 81-83
VAN CUTSEM O., MERRILL W.W.
Aerobic gram positive infections
Current Therapy Disease – B.C. Deckers Inc.
Toronto. Philadelphia – R.M. Cherniak, 372 pages - 189
VAN CUTSEM O.,, LEDENT C., MAIRESSE M.
Le granulome hyalinisant du poumon.
Rev. Mal. Resp. 1990, 7, 279-282
SCULIER J.-P., PAESMANS M., BUREAU G., DABOUIS G., LIBERT P., VANDERMOTEN G.,
VAN CUTSEM O., BERCHIER M.-C., RIES F., MICHEL J., SERGYSELS R., MOMMEN P.,
KLASTERSKY J.
Une chimiothérapie hebdomadaire avec de multiples médicaments ou un
traitement de chimiothérapie standard : résultats d‘une étude phase III conduite
dans le cancer bronchique à petites cellules par l’European Lung Cancer Working
Party.
Rev. Mal. Resp. 1994, 11 : 257-261
KLASTERSKY J., SCULIER J.-P., RIES F., DABOUIS G., LIBERT P., SCHMERBER J., THIRIAUX
J., BERCHIER M.-C., BUREAU G., VAN CUTSEM O., TAGNON A., SERGYSELS R., MOMMEN
P., PAESMANS M. for the European Lung Cancer Working party.
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5fluorouracil.
Annals of Oncology – 1994, 5 : 641-643.
SCULIER J.-P., PAESMANS M., LIBERT P., BUREAU G., DABOUIS G., THIRIAUX J., MICHEL
J., VAN CUTSEM O., SCHMERBER J., GINER V., VERCHIER M.-C., SERGYSELS R.,
MOMMEN P., KLASTERSKY J. for the European Lung Cancer Working party.
Long-term survival after chemotherapy containing platinum derivatives in patient
with advanced unresectable non small cell lung cancer.
Eur. J. Cancer. 1994, 30A : 1342-1347.
KLASTERSKY J., SCULIER J.-P., RIES F., DABOUIS G., LIBERT P., SCHMERBER J., THIRIAUX J.,
BERCHIER M.-C., BUREAU G., VAN CUTSEM O., TAGNON A., SERGYSELS R., MOMMEN P.,
PAESMANS M.
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5
fluorouracile : a regimen associated with majour toxicity in patients with advance
non-small cell lung cancer.
SCULIER J.-P., BUREAU G., GINER V., THIRIAUX J., MICHEL J., BERCHIER M.-C., VAN
CUTSEM O., KÜSTNER U., KROLL F., MOMMEN P., PAESMANS M. , KLASTERSKY J.
Induction chemotherapy with ifosfamide, etoposide, ans anthracycline for small cell
lung.
Experience of the European Lung Cancer Working Party.
Sem. Oncol. 1995 – 22 (suppl.2) : 18-22.
PAESMANS M., SCULIER J.-P., LIBERT P., BUREAU G., DABOUIS G., THIRIAUX J., MICHEL J.,
VAN CUTSEM O., SERGYSELS R. , MOMMEN P. , KLASTERSKY for the European Lung
Cancer Working party.
Prognostic factors for survival in advance non small cell lung cancer ; uni-and
multivariate analyses including recpam analysis in 1052 patients.
J. Clin. Oncol 1995 – 13 : 1221-1230
Update pour Classic Papers and Current Comments : 1997, 2 (1) : 124-134 –
(Highlights of lung cancer research).
SCULIER J.-P., PAESMANS M., BUREAU G., GINER V., LECOMPTE J., MICHEL J., BERCHIER
M.-C., VAN CUTSEM O., KÜSTNER U., KROLL F., SERGYSELS R., MOMMEN P., KLASTERSKY
Y. for the European Lung Cancer Working Party.
A randomized trial comparing induction chemotherapy versus induction
chemotherapy followed by maintenance chemotherapy in small cell cancer.
J. Clin. Oncol. 1996, 14 :2337-2344.
BORGES M., SCULIERS J.-P., PAESMANS M., LIBERT P., BUREAU G., DABOUIS L., THIRIAUX
J., MICHEL J., VAN CUTSEM O., SCHMERBER J., GINER V., BERCHIER M.-C., SERGYSELS
R., MOMMEN P., KLASTERSKY J. for the European Lung Cancer Working Party.
Prognostic factors for response to chemotherapy containing platinum derivatives in
patients with unresectable non-small cell lung cancer (NSCLC)
Lung Cancer 1996, 16 :21-33
PAESMANS M., SCULIER J.-P., LIBERT P., BUREAU G., DABOUIS G., THIRIAUX J., MICHEL
J., VAN CUTSEM O., SERGYSELS R., MOMMEN P and KLASTERSKY J. for the European
Lung Cancer Working Party.
Response to chemotherapy has a discriminant value on the distribution of further
survival for patients with advanced non small cell lung cancer : a ten experience of
the European lung Cancer Working Party.
Eur. J. Cancer 1997, 33 :2326-2332.
SCULIER J.-P., PAESMANS M., NINANE V., GINER V., BUREAU G., LAFITTE J.-J.,
BAUMOHL J., THIRIAUX J., VAN CUTSEM O., RECLOUX P., BERCHIER M.-C., ZACHARIAS
C., MOMMEN P., VAN HOUTTE P., KLASTERSKY J., the European Lung Cancer Working
Party.
Les facteurs pronostiques des cancers bronchiques non à petites cellules au stade
avancé : l’expérience de l’European Lung Cancer Working Party.
Rev.. Mal. Resp. 1997, 14 :445-449.
PAESMANS M., SCULIER J.-P., LECOMPTE J., THIRIAUX J., LIBERT P., SERGYSELS R.,
BUREAU G., DABOUIS G., VAN CUTSEM O., MOMMEN P., NINANE V., KLASTERSKY J, for
the European Lung Cancer Working Party.
Prognostic factors for patients with small cell lung cancer : long-term experience of
the European Lung Cance Working Party.
In «Cancers bronchopulmonaires» (MILLERON B., DEPIERE A.), ARNETTE, VELIZYVILLACOUBLAY, 1998, pp 239-247.
SCULIER J.-P., PAESMANS M., NINANE V., GINER V., BUREAU G., LAFITTE J.-J.
BAUMOHL J., THIRIAUX J., CAN CUTSEM O., RECLOUX P., BERCHIER M.-C., ZACHARIAS
C., MOMMEN P., VAN HOUTTE P., KLASTERSKY J. , the European Lung Cancer Working
Party.
Evaluation of the TN sub-staging in patients with initially unresectable stage III non
small cell lung cancer treated by induction chemotherapy.
Lung cancer, 1998, 22 : 201-203
SCULIER J.-P., PAESMANS M., LAFITTE J.-J., BAUMOHL J., THIRIAUX J., VAN
CUTSEM O., RECLOUX P., BUREAU G., BERCHIER M.-C., ZACHARIAS C.,
MOMMEN
P., BOSSCHAERTS T., BERGHMANS T., VAN HOUTTE P., NINANE V.,
KLASTERSKY J. the European Lung Cancer Working Party.
A randomised phase III trial comparing further chemotherapy to chest irradiation in
objectively responding patients with initially unresectable locoregional non-small cell
lung cancer treated by induction chemotherapy.
Annals of Oncology. 1999 – 10 : 295-303.
SCULIER J.-P., PAESMANS M., LAFITTE J.-J., BAUMOHL J., THIRIAUX J., VAN
CUTSEM O., RECLOUX P., BUREAU G., BERCHIER M.-C., ZACHARIAS C.,
MOMMEN P., BOSSCHAERTS T., BERGHMANS T., VAN HOUTTE P., NINANE V.,
KLASTERSKY J. - the European Lung Cancer Working Party.
Prognostic factors analysis for response to chemotherapy and survival in a
prospective cohort of patients with unresectable locoregional non small cell lung
cancer initially treated by induction chemotherapy.
Rev. Oncologia 1999, 1, 92-100.
PAESMANS M., SCULIER J.-P., LECOMTE J., THIRIAUX J., LIBERT P., SERGYSELS R., BUREAU
G., DABOUIS G., VAN CUTSEM O., MOMMEN P., NINANE V., KLASTERSKY J. for the
European Lung Cancer Working Party.
Prognostic factors for pataients with small cell lung cancer : analysis of a serie of 763
patients included in 4 consecutive pospective trials and with a minimum follow-up of
75 years.
Cancer 2000, 89 : 523-533
SCULIER J.-P., PAESMANS M., LECOMTE J., VAN CUTSEM O., LAFITTE J.-J., BERGHMANS
T., KOUMAKIS G., FLORIN M.-C., THIRIAUX J., MICHEL J., GINER V., BERCHIER M.-C.,
MOMMEN P., NINANE V., KLASTERSKY J. for the European Lung Cancer Working Party.
A three-arm phase III randomised trial assessing, in patients with extensive-disease
small-cell lung cancer, accelerated chemotherapy with support of haematological
growth factor or oral antibiotics.
British Journal of Cancer 2001, 88 : 1444-1451.
SCULIER J.-P., BERGHMANS T, LAFITTE J.-J., RICHEZ M., RECLOUX P., VAN CUTSEM O.,
NINANE V., MOMMEN P., PAESMANS M., KLASTERSKY J. for the European Lung Cancer
Working Party.
A phase III study testing paclitaxel as second-line single agent treatment for patients
with advanced non-small cell lung cancer failing after a first-line chemotherapy.
Lung cancer, 2002 37 : 73-77.
SCULIER J.-P, LAFITTE J.-J., LECOMTE J., BERGHMANS T., THIRIAUX J., VAN CUTSEM O.,
EFREMIDIS A., NINANE V., PAESMANS M., MOMMEN P., KLASTERSKY for the European
Lung Cancer Working Party.
A phase II randomised trial comparing the cisplatin-etoposide combination
chemotherapy with or without carboplatin as second-line therapy for small-cell lung
cancer.
Annals of Oncology, 2002, 13-1454-1459